In this file photo, a patient receives an injection of a potential vaccines against the novel coronavirus at the Institute for Tropical Medicine at the University Hospital of Tübingen. (Photo by Christoph Schmidt/picture alliance via Getty Images) Trump administration officials would not say why they are investing so heavily in ApiJect’s technology.
The company has made only about 1,000 prototypes to date, and it’s not clear whether those devices can deliver the vaccines that are currently in development.
So far, the leading candidates are using traditional vials to hold the vaccine, and needles and syringes in their clinical trials.RELUCTANT SUPPLIERAdvertisementApiJect founder Marc Koska never intended to vaccinate the United States.